Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials
These results highlight the durability, long-term efficacy, safety, and overall benefits of B/F/TAF in PWH ≥ 50 years of age.
Authors
- Bhumi Gandhi‐Patel
- Jürgen K. Rockstroh (ORCID: https://orcid.org/0000-0003-2858-3888)
- Amy R. Weinberg
- Samir K. Gupta (ORCID: https://orcid.org/0000-0001-6031-8705)
- Princy Kumar (ORCID: https://orcid.org/0000-0002-5994-2727)
- Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
- Hui Liu (ORCID: https://orcid.org/0000-0002-5531-3640)
- Cissy M. Kityo
Institutions
- Georgetown University (US)
- University Hospital Bonn (DE)
- Georgetown University Medical Center (US)
- Gilead Sciences (United States) (US)
- Joint Clinical Research Centre (UG)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1186/s12879-025-11476-3
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Gilead Sciences